Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 401–500 of 785
Guthrie, R. M. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1044756 · Cited by 19
Ram, H., Jaipal, N., Kumar, P., Deka, P., Kumar, S., Kashyap, P., Kumar, S., Singh, B. P., Alqarawi, A. A., Hashem, A., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191203161509 · Cited by 15
Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis
Zhan, M., Xu, T., Wu, F., & Yao, T. (2012) · Journal of Evidence-Based Medicine · doi:10.1111/j.1756-5391.2012.01189.x · Cited by 18
Oh, T. J., Jung, H. S., Bae, J. H., Kim, Y. G., Park, K. S., Cho, Y. M., Park, K. S., & Kim, S. Y. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.6.881 · Cited by 17
Naidoo, P., Wing, J., & Rambiritch, V. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5073 · Cited by 18
Keshavarz, K., Lotfı, F. H., Sanati, E., Salesi, M., Hashemi-Meshkini, A., Jafari, M., Mojahedian, M. M., Najafi, B., & Nikfar, S. (2017) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-017-0189-6 · Cited by 15
Oh, H., Nguyen, H. D., Yoon, I. M., Ahn, B.-R., & Kim, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-00418-z · Cited by 15
Enhanced glycemic control with combination therapy for type 2 diabetes in primary care
Kuritzky, L., & Samraj, G. P. N. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0006-z · Cited by 20
Karyekar, C. S., Frederich, R. C., & Ravichandran, S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12212 · Cited by 18
Syam, Y. M., El‐Karim, S. S. A., Nasr, T., Elseginy, S. A., Anwar, M. M., Kamel, M. M., & Ali, H. F. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170828121018 · Cited by 15
Management of patients with type 2 diabetes
Nelson, S. E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.611797 · Cited by 16
Hou, L.-Q., Zhao, T.-Y., LIU, Y., & Zhang, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2277 · Cited by 15
Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
Gadsby, R. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2313 · Cited by 19
Kim, H. M., Lim, J. S., Lee, B., Kang, E. S., Lee, H. C., & Soo, B. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.84 · Cited by 14
Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus.
Onge, E. S., Miller, S. A., & Clements, E. A. (2012) · PubMed · Cited by 33
Ji, L., Li, L., Ma, J., Li, X., Li, D., Meng, B., Lu, W., Sun, J., Liu, Y., Takayanagi, G., et al. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.222 · Cited by 21
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone
Bailey, C. J., Green, B. D., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.505235 · Cited by 14
Utilizing Current Diagnostic Criteria and Treatment Algorithms for Managing Type 2 Diabetes Mellitus
Kruger, D. F., Boucher, J. L., & Banerji, M. A. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2304 · Cited by 14
Pharmacotherapy of hyperglycemia
Kulasa, K. M., & Henry, R. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903196758 · Cited by 15
An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides
Sivaraman, S. A., & Sabareesh, V. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037287976231212104607 · Cited by 17
Schnell, O., Alawi, H., Battelino, T., Ceriello, A., Diem, P., Felton, A., Grzeszczak, W., Harno, K., Kempler, P., Satman, I., et al. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600323 · Cited by 14
The design of the liraglutide clinical trial programme
Nauck, M. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01573.x · Cited by 14
DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case–Control Study
Kathe, N. J., Shah, A., Said, Q., & Painter, J. T. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0353-5 · Cited by 13
Nauck, M. A., & Vardarli, I. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00004.x · Cited by 12
Glucagon-Like Peptide-1 and its Cardiovascular Effects
Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 15
松嶋, 由., Takeshita, Y., Kita, Y., Otoda, T., Kato, K., Wakakuri, H., Akahori, H., Shimizu, A., Hamaguchi, E., Nishimura, Y., et al. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000190 · Cited by 15
Horii, T., Iwasawa, M., Shimizu, J., & Atsuda, K. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13088 · Cited by 15
Rosenstock, J., Lewin, A. J., Norwood, P. C., Somayaji, V. R., Nguyen, T. T., Teeter, J. G., JOHNSON, S. L., Dai, H. I., & Terra, S. G. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03181.x · Cited by 13
Monnier, L., Colette, C., Comenducci, A., Vallée, D., & Dejager, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0045 · Cited by 16
Moses, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.007 · Cited by 13
Elrishi, M., Khunti, K., Jarvis, J., & Davies, M. (2007) · Practical Diabetes · doi:10.1002/pdi.1181 · Cited by 15
Glucagon‐like peptide‐1‐based therapies: new developments and emerging data
Garber, A. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00921.x · Cited by 17
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Kosheleva, L., Koshelev, D., Lagunas‐Rangel, F. A., Levit, S., Rabinovitch, A., & Schiöth, H. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100044 · Cited by 12
Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
Zeng, D.-K., Xiao, Q., Li, F., Tang, Y.-Z., Jia, C.-L., & Tang, X.-W. (2019) · Bioscience Reports · doi:10.1042/bsr20190980 · Cited by 14
Implications of incretin‐based therapies on cardiovascular disease
Rotz, M., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015) · International journal of clinical practice · doi:10.1111/ijcp.12572 · Cited by 11
Choi, H. Y., Kim, Y. H., Kim, M. J., Lee, S. H., Bang, K., Han, S. Y., Lim, H.-S., & Bae, K. (2014) · Drugs in R&D · doi:10.1007/s40268-014-0054-8 · Cited by 13
Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
Robertson, C. (2011) · Diabetes Spectrum · doi:10.2337/diaspect.24.1.26 · Cited by 14
Kim, S. S., Kim, I. J., Lee, K. J., Park, J. H., Kim, Y. I., Lee, Y. S., Chung, S. C., & Lee, S. J. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12432 · Cited by 12
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Kristin, E. (2016) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci004802201606 · Cited by 18
Lee, S., Gantz, I., Round, E., Latham, M., O’Neill, E. A., Ceesay, P., Suryawanshi, S., Kaufman, K. D., Engel, S. S., & Lai, E. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0219-x · Cited by 12
Frías, J. P., Zimmer, Z., Lam, R. L. H., Amorín, G. S., Ntabadde, C., Iredale, C., O’Neill, E. A., Engel, S. S., Kaufman, K. D., Makimura, H., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13626 · Cited by 13
de Valk, H. W. (2007) · The Review of Diabetic Studies · doi:10.1900/rds.2007.4.126 · Cited by 14
on behalf of the EpiDREAM and INTERHEART investigators, Bailey, S. D., Xie, C., Paré, G., Montpetit, A., Mohan, V., Yusuf, S., Gerstein, H. C., Engert, J. C., & Anand, S. S. (2013) · Diabetologia · doi:10.1007/s00125-013-3142-3 · Cited by 13
Edwards, K. L., Álvarez, C. A., Irons, B. K., & Fields, J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.506 · Cited by 12
Lo, M. C., & Lansang, M. C. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ec9eb2 · Cited by 14
Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management
Lingvay, I., Rhee, C., & Raskin, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_10 · Cited by 13
Hong, J. H., Moon, J. S., Seong, K., & Lim, S. K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110872 · Cited by 13
The older patient with diabetes: a practical approach
Ben‐Yehuda, A., Zinger, A., & Durso, S. C. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2485 · Cited by 13
Odawara, M., Kadowaki, T., Tajima, N., Nishii, M., Taniguchi, T., & Ferreira, J. C. A. (2011) · Diabetology International · doi:10.1007/s13340-011-0029-8 · Cited by 11
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Xu, J., Ling, H., Geng, J., Investigators, Huang, Y., Xie, Y., Zheng, H., Niu, H., Zhang, T., Yuan, J., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14810 · Cited by 11
Shimoda, S., Iwashita, S., Sekigami, T., Furukawa, N., Matsuo, Y., Ichimori, S., Goto, R., Maeda, T., Watanabe, E., Kondo, T., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12151 · Cited by 14
Kim, H. J., Kim, Y. S., Lee, C. B., Choi, M. G., Chang, H., Kim, S. K., Yu, J. M., Kim, T. H., Lee, J. H., Ahn, K. J., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0628-0 · Cited by 12
Lautsch, D., Alsumali, A., McLeod, E. J., Kuang, Y., He, J. N., Singh, R., Nevo, A., Arnet, U. A., Uyei, J., & Rajpathak, S. N. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00975-y · Cited by 12
Ong, S. H., Blüher, M., & Schuetz, A. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s75935 · Cited by 11
Incretin-based Therapy in Chronic Kidney Disease
Pinelli, N. R., Moore, C. L., & Tomasello, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.06.003 · Cited by 13
Lipid Effects of Endocrine Medications
Mihailescu, D. V., Vora, A., & Mazzone, T. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0146-z · Cited by 13
Engel, S. S., Anderson, K. M., Hanson, Musliner, & Steinberg, H. O. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s44330 · Cited by 12
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
Argyrakopoulou, G., & Doupis, J. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0009-6 · Cited by 11
Kumar, S., Pathak, A. K., Saikia, D., & Kumar, A. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/17027.6888 · Cited by 16
What's new in ... clinical pharmacology and therapeutics.
Chawla, P. S., & Kochar, M. S. (1996) · PubMed · Cited by 11
Beyond insulin replacement: addressing the additional needs of the diabetes patient
DAILEY, G. E. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00847.x · Cited by 12
(2011) · Wiley eBooks · doi:10.1002/9781119950424.ch5 · Cited by 12
Garber, A. J. (2011) · PubMed · Cited by 11
Current state of type 2 diabetes management.
Molitch, M. E. (2013) · PubMed · Cited by 13
Freeman, J. S. (2010) · PubMed · Cited by 10
Peterson, G. M. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.653392 · Cited by 11
Grunberger, G. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1727-5 · Cited by 10
Clinical review of sitagliptin: a DPP-4 inhibitor.
Garg, K., Tripathi, C. D., & Kumar, S. (2013) · PubMed · Cited by 12
Fujita, K., Kaneko, M., & Narukawa, M. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0478-8 · Cited by 12
Wang, L., Wang, H., Liu, Q., Hua, W.-C., & Li, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.002 · Cited by 10
Yardstick for managing cough, part 1
Irwin, R. S., Oppenheimer, J., Dunlap, W., Lieberman, P., & Chang, A. B. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.12.008 · Cited by 11
Salsali, A., & Pratley, R. E. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0512 · Cited by 10
Boyle, P. J., & Freeman, J. S. (2007) · PubMed · Cited by 13
Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2
Scheen, A. J., Radermecker, R. P., Philips, J., & Paquot, N. (2007) · JMIG · doi:10.53738/revmed.2007.3.122.1884 · Cited by 10
Malesker, M. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.193 · Cited by 10
Henry, R. R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802212981 · Cited by 11
Kim, W. J., Park, C., Jeong, E. H., Seo, J. Y., Seol, J. S., Park, S. E., Rhee, E., Lee, W., Oh, K. W., Park, S. W., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.290 · Cited by 9
Fluorine-Containing Diazines in Medicinal Chemistry and Agrochemistry
Volochnyuk, D. M., Grygorenko, O. O., & Gorlova, A. O. (2014) · Springer eBooks · doi:10.1007/978-3-319-04435-4_7 · Cited by 9
Kaku, K., Shimoda, M., Osonoi, T., Iwamoto, M., & Kaneto, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16336 · Cited by 13
Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
Cornell, S. A. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01302.x · Cited by 9
Shima, K., Komatsu, M., Noma, Y., & Miya, K. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1364 · Cited by 9
Green, D. E. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60008-9 · Cited by 10
Schwaiger, E., Klaus, C., Matheeussen, V., Baranyi, U., Pilat, N., Ramsey, H. E., Korom, S., Meester, I. D., & Wekerle, T. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.10.010 · Cited by 9
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
Pelluri, R., Kongara, S., Nagasubramanian, V. R., Mahadevan, S., & Chimakurthy, J. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02003-9 · Cited by 14
Fukui, K., Kawahito, H., Wakana, N., Kikai, M., Terada, K., Yamamoto, K., Irie, D., Kato, T., Miyagawa, S., & Yamada, H. (2015) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320315587180 · Cited by 10
Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
Åhrén, B. (2013) · European Diabetes Nursing · doi:10.1002/edn.221 · Cited by 9
Bekur, R., Nagaraja, M. V., Shivashankara, K., & Stanley, W. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.70405 · Cited by 9
Hirao, K., Maeda, H., Shirabe, S., Yamamoto, R., Hirao, T., Hirao, S., Yamauchi, M., & Arai, K. (2012) · Japanese Clinical Medicine · doi:10.4137/jcm.s8571 · Cited by 12
Gao, W., Wang, Q., & Yu, S. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0465-1 · Cited by 9
Scheen, A. J., & Gaal, L. F. V. (2008) · PubMed · Cited by 23
An in-depth review of PPARγ modulators as anti-diabetes therapeutics
Jangra, A., Babu, B., Selvaraj, D., Byran, G., Rajan, S., Jangra, S., & Malakar, V. K. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2508152 · Cited by 14
Grunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12046 · Cited by 8
A systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
Turan, B., Durak, A. T., Olğar, Y., & Tuncay, E. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04474-5 · Cited by 9
Recent advances in glucose-lowering treatment to reduce diabetic kidney disease
Hanssen, N. M. J., Russell, N., & Cooper, M. E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041502 · Cited by 8
Arai, K., Maeda, H., Sirabe, S.-I., Yamamoto, R., Yamauchi, M., Hirao, T., Hirao, S., & Hirao, K. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0287 · Cited by 9
Ah, B., & Orme, M. E. (2014) · Internal Medicine Open Access · doi:10.4172/2165-8048.s6-006 · Cited by 9
Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review
Sidorov, A. V. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-25-24-48 · Cited by 12
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.